Ocular Melanoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

 Ocular melanoma, a type of cancer that originates in the pigment-producing cells of the eye or surrounding area, is a relatively uncommon condition. The two subtypes of ocular melanoma are the uveal and conjunctival forms, which display notable differences. The presentation of OM can vary depending on its location and may manifest as symptoms such as blurred vision, reduced visual field, flashing lights, redness, discomfort, pain, or a sensation of pressure. Several risk factors for the development of OM have been identified, including fair skin, atypical skin moles, light eye color, iris moles, freckles, and exposure to sun or tanning, as well as a genetic correlation at the CLPTM1L locus between uveal and cutaneous melanoma. The primary mechanisms underlying the development of OM may involve oxidative damage to pigmented tissues and genetic alterations resulting from adenine-to-cytosine mutations in uveal melanoma or adenine-to-thymine mutations in ciliochoroidal melanoma. Melanomas may also arise from pre-existing benign lesions known as nevi. The size of the melanoma guides the choice of treatment, which may include plaque radiation therapy, particle beam radiotherapy, transpupillary thermotherapy, laser photocoagulation, gamma knife stereotactic radiosurgery, local surgical resection, or enucleation. A definitive diagnosis of OM requires a biopsy, as several other conditions may present similarly, including choroidal nevus, iris nevus, retinal pigment epithelium hypertrophy, and various benign or malignant lesions. Approximately half of the patients with ocular melanoma will develop metastatic disease within 10 to 15 years of diagnosis, with a smaller proportion developing metastases later, 20 to 25 years after initial diagnosis. Metastatic disease is universally fatal.

·       The incidence of uveal and conjunctival melanoma is estimated to be 5 cases per million and 0.33 cases per million in the USA. Males have a 30% greater incidence of uveal melanoma than females.

Thelansis’s “Ocular Melanoma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Ocular Melanoma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Ocular Melanoma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Ocular Melanoma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Ocular Melanoma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032